Wegovy 7.2 mg: What Patients Should Know About the Higher Dose

Wegovy now has a higher-dose option called Wegovy HD, which delivers 7.2 mg of semaglutide once weekly. In March 2026, the FDA approved this higher dose for long-term weight loss and long-term weight maintenance in certain adults with obesity, or adults with overweight plus at least one weight-related medical condition.

What is Wegovy 7.2 mg?

Wegovy 7.2 mg is still the same medication family as standard Wegovy. The difference is that it is a higher weekly maintenance dose. According to the manufacturer’s patient information, this higher dose may be considered for adults who still need more weight loss after they have already been on Wegovy 2.4 mg for at least 4 weeks.

How much weight loss was seen?

In the company’s weight-loss study, adults using Wegovy 7.2 mg along with diet and exercise lost about 19% of their starting body weight on average over 72 weeks. The same page also says that about 1 in 3 adults on the 7.2 mg dose lost 25% or more of their starting weight.

Why would someone consider the higher dose?

Some patients do well on Wegovy 2.4 mg and are happy staying there. Others tolerate it well but feel like their progress has slowed before they reach their goal. For those patients, the higher 7.2 mg dose may offer another option to discuss with their healthcare provider. The manufacturer specifically describes it as a possible step up for adults who want to lose more weight after already being on 2.4 mg.

What side effects were reported?

The most common side effects with Wegovy 7.2 mg were mostly stomach-related, similar to what many patients already know about semaglutide. The FDA-approved label lists common side effects including nausea, vomiting, constipation, abdominal pain, fatigue, headache, dizziness, hair loss, and gas.

One side effect that stood out more with the higher dose was dysesthesia, which means unusual skin sensations such as burning, tingling, heightened sensitivity, or discomfort. The FDA label reported this in 22% of patients on Wegovy 7.2 mg, compared with 6% on Wegovy 2.4 mg and 0.3% on placebo.

Did some people stop treatment because of side effects?

Yes. According to the FDA-approved prescribing information, 5% of patients on Wegovy 7.2 mg stopped treatment because of side effects. The most common reason for stopping was gastrointestinal side effects.

Is Wegovy 7.2 mg right for everyone?

Not necessarily. A higher dose is not automatically better for every patient. Some people do well on lower doses, and some people may not tolerate higher doses well. This is something that should be decided based on your progress, side effects, medical history, and overall goals. The FDA label also keeps the same important warnings and precautions that apply to Wegovy more broadly.

Important safety reminders

Wegovy should not be used with other semaglutide-containing medications or with other GLP-1 receptor agonists. It is also contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.

Final thoughts

Wegovy 7.2 mg gives some patients another FDA-approved option when standard Wegovy is not enough. The higher dose was associated with greater average weight loss in studies, but it also comes with a higher chance of side effects, especially stomach-related symptoms and unusual skin sensations. The best dose is the one that balances effectiveness with tolerability for the individual patient.